Lung cancer

TAS6417-301

Randomized, Controlled, Open-label, Phase 3, Global Multi-;Center Trial to Assess the Efficacy and Safety of Zipalertinib;plus Chemotherapy versus Chemotherapy alone, in Patients;with Previously Untreated, Locally Advanced or Metastatic;Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with;Epidermal Growth Factor Receptor (EGFR) Exon 20;Insertion (ex20ins) Mutations.
  • Open at Paris since : 27/06/2024
  • Target : Adult
  • Phase : Phase III

Trial description

To determine the recommended dose of;zipalertinib in combination with;pemetrexed and a platinum agent to be;studied in the Phase 3 portion of the study;À Incidence of dose-limiting toxicities (DLTs) graded;according to the NCI-Common Terminology Criteria of;Adverse Events (CTCAE) v5.0 during Cycle 1.
Url of the trial

Main investigator

NICOLAS GIRARD

Professeur - Médecin

Contact